ARGININE-VASOPRESSIN PRODUCES RENAL VASODILATION VIA V(2)-RECEPTORS IN CONSCIOUS DOGS

被引:58
作者
NAITOH, M
SUZUKI, H
MURAKAMI, M
MATSUMOTO, A
ICHIHARA, A
NAKAMOTO, H
YAMAMURA, Y
SARUTA, T
机构
[1] KEIO UNIV,SCH MED,DEPT INTERNAL MED,35 SHINANOMACHI,SHINJUKU KU,TOKYO 160,JAPAN
[2] OTSUKA PHARMACEUT CO LTD,TOKUSHIMA INST NEW DRUG RES 2,TOKUSHIMA 77101,JAPAN
来源
AMERICAN JOURNAL OF PHYSIOLOGY | 1993年 / 265卷 / 04期
关键词
RENAL BLOOD FLOW; ARGININE VASOPRESSIN RECEPTOR ANTAGONIST; WATER DEPRIVATION;
D O I
10.1152/ajpregu.1993.265.4.R934
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
In conscious dogs, 36-h water deprivation induced a significant increase in renal blood flow (RBF) with elevation of the plasma arginine vasopressin (AVP) concentration to 9.6 +/- 1.8 pg/ml. To simulate such a condition, a mild elevation of plasma AVP was produced by infusing AVP intravenously at a dose of 0.1 ng.kg-1.min-1 for 20 min. The plasma AVP concentration then increased to 6.8 +/- 0.7 pg/ml. This dose of AVP increased the RBF by 21.7 +/- 2.6% and decreased the renal vascular resistance by 18.1 +/- 2.3% without significant changes in mean arterial pressure, cardiac output, or heart rate. The mechanism of this renal vasodilatory action was examined using newly developed, orally effective, selective AVP antagonists OPC-21268 (a V1-receptor antagonist) and OPC-31260 (a V2-receptor antagonist). In 36-h water-deprived dogs, V2-receptor blockade with OPC-31260 significantly decreased the RBF by 20.5 +/- 2.6% without significant changes in cardiac output. The exogenous AVP-induced renal vasodilatory response tended to be augmented when V1 receptors were blocked by pretreatment with OPC-21268, but the change did not achieve statistical significance. On the other hand, V2-receptor blockade by either pretreatment with OPC-31260 or simultaneous infusion of OPC-31260 inhibited this vasodilatory response. Furthermore, intravenous infusion of 1-desamino-8-D-arginine vasopressin (DDAVP) at a dose of 0.3 ng-kg-1.min-1 for 20 min significantly increased the RBF by 36.5 +/- 1.7%, and this DDAVP-induced renal vasodilation was inhibited by simultaneous infusion of V2-receptor antagonist. These results suggest that AVP increases the RBF mediated by V2-receptor-related responses in conscious dogs.
引用
收藏
页码:R934 / R942
页数:9
相关论文
共 36 条
[1]  
ABBOUD FM, 1990, BLOOD VESSELS, V27, P106
[2]   HEMODYNAMIC AND COAGULATION RESPONSES TO 1-DESAMINO[8-D-ARGININE] VASOPRESSIN IN PATIENTS WITH CONGENITAL NEPHROGENIC DIABETES-INSIPIDUS [J].
BICHET, DG ;
RAZI, M ;
LONERGAN, M ;
ARTHUS, MF ;
PAPUKNA, V ;
KORTAS, C ;
BARJON, JN .
NEW ENGLAND JOURNAL OF MEDICINE, 1988, 318 (14) :881-887
[3]   HEMODYNAMIC-RESPONSES TO VASOPRESSINERGIC ANTAGONISM IN WATER-DEPRIVED CONSCIOUS RATS [J].
BRIZZEE, BL ;
HARRISONBERNARD, L ;
PRETUS, HA ;
CLIFTON, GG ;
WALKER, BR .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (01) :R46-R51
[4]   BLOCKING EFFECTS OF OPC-21268 AND OPC-31260 (VASOPRESSIN V1-RECEPTOR AND V2-RECEPTOR ANTAGONISTS) ON VASOPRESSIN-INDUCED CONSTRICTIONS IN ISOLATED, PERFUSED DOG FEMORAL ARTERIES [J].
CHIBA, S ;
TSUKADA, M .
JAPANESE JOURNAL OF PHARMACOLOGY, 1992, 59 (01) :133-135
[5]   RENAL MICROVASCULAR EFFECTS OF VASOPRESSIN AND VASOPRESSIN ANTAGONISTS [J].
EDWARDS, RM ;
TRIZNA, W ;
KINTER, LB .
AMERICAN JOURNAL OF PHYSIOLOGY, 1989, 256 (02) :F274-F278
[6]   INHIBITION OF MUSCLE SYMPATHETIC-NERVE ACTIVITY IN HUMANS BY ARGININE VASOPRESSIN [J].
FLORAS, JS ;
AYLWARD, PE ;
ABBOUD, FM ;
MARK, AL .
HYPERTENSION, 1987, 10 (04) :409-416
[7]   ENDOTHELIUM-DERIVED RELAXING FACTOR RELEASE ON ACTIVATION OF NMDA RECEPTORS SUGGESTS ROLE AS INTERCELLULAR MESSENGER IN THE BRAIN [J].
GARTHWAITE, J ;
CHARLES, SL ;
CHESSWILLIAMS, R .
NATURE, 1988, 336 (6197) :385-388
[8]   RENAL VERSUS HINDQUARTER HEMODYNAMIC-RESPONSES TO VASOPRESSIN IN CONSCIOUS RATS [J].
HARRISONBERNARD, LM ;
BRIZZEE, BL ;
CLIFTON, GG ;
WALKER, BR .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1990, 16 (05) :719-726
[9]   VASOPRESSIN-MEDIATED FOREARM VASODILATION IN NORMAL HUMANS - EVIDENCE FOR A VASCULAR VASOPRESSIN V2 RECEPTOR [J].
HIRSCH, AT ;
DZAU, VJ ;
MAJZOUB, JA ;
CREAGER, MA .
JOURNAL OF CLINICAL INVESTIGATION, 1989, 84 (02) :418-426
[10]   EFFECTS OF OPC-21268, AN ORALLY EFFECTIVE VASOPRESSIN V1 RECEPTOR ANTAGONIST IN HUMANS [J].
IMAIZUMI, T ;
HARADA, S ;
HIROOKA, Y ;
MASAKI, H ;
MOMOHARA, M ;
TAKESHITA, A .
HYPERTENSION, 1992, 20 (01) :54-58